The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Aducanumab: Appropriate Use Recommendations Update
Open accessAbstract
Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab Appropriate Use Recommendations (AURs) have been published and have helped guide best practices for use of aducanumab. As real-world use has occurred and more information has accrued, the AURs require refinement. We update the AURs to better inform appropriate patient selection and improve shared decision-making, safety monitoring, and risk mitigation in treated patients. Based on evolving experience we emphasize the importance of detecting past medical conditions that may predispose to amyloid related imaging abnormalities (ARIA) or may increase the likelihood of ARIA complications including autoimmune or inflammatory conditions, seizures, or disorders associated with extensive white matter pathology. The apolipoprotein E ε4 (APOE4) genotype is strongly associated with ARIA and exhibits a gene dose effect. We recommend that clinicians perform APOE genotyping to better inform patient care decisions, discussions regarding risk, and clinician vigilance concerning ARIA. As most ARIA occurs during the titration period of aducanumab, we suggest performing MRI before the 5th, 7th, 9th, and 12th infusions to improve detection. Uncommonly, ARIA may be recurrent or serious; we suggest additional parameters for treatment discontinuation taking these observations into account. It is important to continue to learn from the real-world use of aducanumab and the AURs will continue to evolve as new information becomes available. This AUR update does not address efficacy, price, or insurance coverage and is provided to assist clinicians to establish best practices for use of aducanumab in the treatment of patients with mild cognitive impairment and mild Alzheimer's dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553 · cited 1×
“Use of brief tools such as the Montreal Cognitive Assessment (MoCA) (13) may be helpful in detecting cognitive impairment.”
MethodSelf-citationKok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“Patients appropriate for treatment with aducanumab should have the clinical syndrome of MCI due to AD or mild AD dementia (8, 9).”
BackgroundDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 15×
“Two other anti-amyloid monoclonal antibodies --- lecanemab, donanemab --- will be presented to the FDA for consideration for accelerated approval based on clinical data accompanied by Aβ plaque lowering demonstrated on Aβ PET (37, 38).”
BackgroundResultInfluentialSelf-citationThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · cited 1×
“APOE4 interacts with amyloid to decrease clearance from the brain and increase amyloid aggregation and deposition, and APOE4 is implicated in non-amyloid dependent pathways including effects on the tau protein, tau-mediated neurodegeneration, alpha-synuclein, TAR DNA binding protein 43 (TDP-43), and microglia (24, 25).”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“Antibodies such as solanezumab that target monomeric Aβ peptides rather than larger species do not dramatically reduce amyloid plaque load, are not associated with ARIA, and appear to differ substantially from plaque-lowering antibodies (40).”
BackgroundCerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847
Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619
Self-citationSperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512
Self-citationApolipoprotein E in Alzheimer's Disease: An Update
Yu, J.-T., Tan, L., & Hardy, J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014300 · Cited by 394
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375 · cited 1×
“There is good correspondence between amyloid plaque burden as determined by amyloid PET and CSF amyloid abnormalities in the diagnosis of AD (21).”
BackgroundSelf-citationAducanumab: Appropriate Use Recommendations
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.41 · Cited by 316
Self-citationPrevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5216 · Cited by 290 · cited 1×
“Up to 50% of patients with MCI and 20-25% of those with dementia attributed to AD do not have amyloid plaques indicative of the presence of AD-type pathology (16-18).”
BackgroundSelf-citationApproval of Aducanumab for Alzheimer Disease—The FDA’s Perspective
Dunn, B., Stein, P., & Cavazzoni, P. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.4607 · Cited by 246
Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212 · cited 1×
“Another antiamyloid monoclonal antibody --- gantenerumab --- will complete its clinical development program in 2022 (39).”
BackgroundAmyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi, M., Cecchetti, G., Spinelli, E. G., Vezzulli, P., Falini, A., & Agosta, F. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5205 · Cited by 189 · cited 4×
“These data and accumulating real-world experience indicate that individuals who are APOE4 homozygous are at greater risk of ARIA-E occurrence and may have a higher likelihood for ARIA-E recurrence, ARIA-E severity, and ARIA-E-related serious adverse events (4, 5).”
BackgroundInfluentialDifferences between clinical trials and postmarketing use
Martin, K., Bégaud, B., Latry, P., Miremont‐Salamé, G., Fourrier, A., & Moore, N. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01953.x · Cited by 157
APOE-ε2 and APOE-ε4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature
Nelson, P. T., Pious, N. M., Jicha, G. A., Wilcock, D. M., Fardo, D. W., Estus, S., & Rebeck, G. W. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829a25b9 · Cited by 150
Aducanumab for the treatment of Alzheimer's disease
Tagliapietra, M. (2022) · Drugs of Today · doi:10.1358/dot.2022.58.10.3422314 · Cited by 24 · cited 2×
“In combined data from the EMERGE and ENGAGE clinical trials, 20.3% of APOE4 noncarriers and 43% of APOE4 carriers developed ARIAE (27).”
BackgroundInfluential
Research works printed but not linked: 17
- VandeVrede, 2020, Symptomatic amyloid-related imaging abnormalities in an APOE epsilon4/epsilon4 patient treated with aducanumab, Alzheimers Dement (Amst)., 12, e12101
- Barakos, 2022, Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer•s disease treated with anti-amyloid beta therapy, J Prev Alz Dis, 10.14283/jpad.2022.21 · DOI · Paper page
- Salvarani, 2013, Abeta-related angiitis: comparison with CAA without inflammation and primary CNS vasculitis, Neurology, 81, 1596, 10.1212/WNL.0b013e3182a9f545 · DOI · Paper page
- Folstein, 1975, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- Asselin, 2022, Validation of an magnetic resonance imaging acquisition and review protocol for Alzheimer•s disease and related disorders, Can Assoc Radiol J., 70, 172, 10.1016/j.carj.2018.10.008 · DOI
- Zhou, 2020, The study on analysis of risk factors for severity of white matter lesions and its correlation with cerebral microbleeds in the elderly with lacunar infarction, Medicine (Baltimore)., 99, e18865, 10.1097/MD.0000000000018865 · DOI
- Sevigny, 2016, Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial, Alzheimer Dis Assoc Disord, 30, 1, 10.1097/WAD.0000000000000144 · DOI
- Degenhardt, 2016, Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia, Psychosomatics, 57, 208, 10.1016/j.psym.2015.12.002 · DOI · Paper page
- Johnson, 2013, Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer•s Association, Alzheimers Dement, 9, e1, 10.1016/j.jalz.2013.01.002 · DOI · Paper page
- Leuzy, 2022, Blood-based biomarkers for Alzheimer•s disease, EMBO Mol Med, 14, e14408, 10.15252/emmm.202114408 · DOI · Paper page
- Yang, 2018, Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study, Lancet Neurol, 17, 773, 10.1016/S1474-4422(18)30251-5 · DOI
- Largent, 2021, Disclosing genetic risk of Alzheimer•s disease to cognitively unimpaired older adults: indings from the study of knowledge and reactions to APOE testing (SOKRATES II), J Alzheimers Dis, 84, 1015, 10.3233/JAD-210675 · DOI
- Vears, 2021, Return of individual research results from genomic research: A systematic review of stakeholder perspectives, PLoS One, 16, e0258646, 10.1371/journal.pone.0258646 · DOI
- Green, 2009, Disclosure of APOE genotype for risk of Alzheimer•s disease, N Engl J Med, 361, 245, 10.1056/NEJMoa0809578 · DOI · Paper page
- Gaubert, 2021, Decision-making competence in patients with Alzheimer•s disease: a review of the literature, Neuropsychol Rev, 31, 267, 10.1007/s11065-020-09472-2 · DOI
- Chiong, 2021, Decisions with patients and families regarding aducanumab in Alzheimer disease, with recommendations for consent: AAN position statement, Neurology
- Schneider, 1997, Eligibility of Alzheimer•s disease clinic patients for clinical trials, J Am Geriatr Soc, 45, 923, 10.1111/j.1532-5415.1997.tb02960.x · DOI
Cited by
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
Lecanemab: Appropriate Use Recommendations
Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.30 · Cited by 961
Self-citationApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
Self-citationAnti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Cummings, J., Osse, A. M. L., Cammann, D., Powell, J., & Chen, J. (2024) · BioDrugs · doi:10.1007/s40259-023-00633-2 · Cited by 368
Self-citation
Metadata
- Authors
- Cummings, J., Rabinovici, G. D., Atri, A., Aisen, P., Apostolova, L. G., Hendrix, S., Sabbagh, M., Selkoe, D., Weiner, M., & Salloway, S.
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 9
- Issue
- 2
- Pages
- 221-230
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W4226454711
- Cited by
- 196
- References
- 23
- FWCI
- 21.82
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.